Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
This is an international, multicentre, double-blind, controlled, randomized phase II study comparing the efficacy and safety of fulvestrant in combination with palbociclib versus fulvestrant plus placebo in postmenopausal women with HR-positive/HER2-negative metastatic breast cancer who have received ≥5 years of endocrine therapy in the adjuvant setting as treatment for early disease and remained disease free for \> 12 months following its completion or have \"de novo\" metastatic disease.
Epistemonikos ID: 56846de07d6580e6a3d2788ac5dcc5b377a40524
First added on: May 12, 2024